1,1-二甲基乙基[(1S)-3,3,3-三氟-1-(羟甲基)丙基]氨基甲酸酯 | 610272-57-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1,1-二甲基乙基[(1S)-3,3,3-三氟-1-(羟甲基)丙基]氨基甲酸酯
• 中文别名: N-[(2S)-4,4,4-三氟-1-羟基丁烷-2-基]氨基甲酸叔丁酯
• 英文名称: 1,1-dimethylethyl [(1S)-3,3,3-trifluoro-1-(hydroxymethyl)propyl]carbamate
• 英文别名: (2S)-2-(tert-butoxycarbonyl)amino-4,4,4-trifluorobutan-1-ol；(S)-tert-butyl 4,4,4-trifluoro-1-hydroxybutan-2-ylcarbamate；tert-butyl N-[(2S)-4,4,4-trifluoro-1-hydroxybutan-2-yl]carbamate
• CAS: 610272-57-6
• 化学式: C₉H₁₆F₃NO₃
• 分子量: 243.226
• InChiKey: YQODVUUZNPHLQT-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1,1-二甲基乙基[(1S)-3,3,3-三氟-1-(羟甲基)丙基]氨基甲酸酯 在 jones reagent 作用下， 以 丙酮 为溶剂， 以80%的产率得到(S)-2-((tert-butoxycarbonyl)amino)-4,4,4-trifluorobutanoic acid
  参考文献：
  名称：

  抗-4,4,4-三氟苏氨酸和2-氨基-4,4,4-三氟丁酸的两种对映异构体的不对称合成。

  摘要：

  成功开发了一种短而有效的对映体，其合成抗4,4,4-三氟苏氨酸和2-氨基-4,4,4-三氟丁酸的对映体。苄基保护的溴代烯烃4的三氟甲基化以良好的收率提供了关键的中间体三氟甲基化的反式二取代烯烃2。然后，该序列涉及Sharpless不对称二羟基化，环状硫酸盐与NaN（3）的亲核打开，钯催化的选择性氢化和氧化。

  DOI：

  10.1021/jo0344384
• 作为产物：
  描述：

  (S)-2-((tert-butoxycarbonyl)amino)-4,4,4-trifluorobutanoic acid 在 氯甲酸乙酯 、 三乙胺 、 锂硼氢 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 生成 1,1-二甲基乙基[(1S)-3,3,3-三氟-1-(羟甲基)丙基]氨基甲酸酯
  参考文献：
  名称：

  [EN] CANNABINOID RECEPTOR MODULATORS
  [FR] MODULATEURS DES RÉCEPTEURS DES CANNABINOÏDES

  摘要：

  提供了一些在治疗疼痛方面有用的方法，包括给予化合物Ia的复方及其药物组合物，以调节大麻素CB2受体的活性。

  公开号：

  WO2012116279A1

文献信息

• Asymmetric Synthesis of Both Enantiomers of <i>a</i><i>nti</i>-4,4,4-Trifluorothreonine and 2-Amino-4,4,4-trifluorobutanoic Acid
  作者：Zhong-Xing Jiang、Ying-Ying Qin、Feng-Ling Qing

  DOI：10.1021/jo0344384

  日期：2003.9.1

  A short and efficient enantioselective synthesis of both enantiomers of anti-4,4,4-trifluorothreonine and 2-amino-4,4,4-trifluorobutanoic acid was successfully developed. Trifluoromethylation of benzyl-protected bromoalkene 4 provided key intermediate trifluoromethylated trans-disubstituted alkene 2 in good yield. The sequence then involved Sharpless asymmetric dihydroxylation, nucleophilic opening

  成功开发了一种短而有效的对映体，其合成抗4,4,4-三氟苏氨酸和2-氨基-4,4,4-三氟丁酸的对映体。苄基保护的溴代烯烃4的三氟甲基化以良好的收率提供了关键的中间体三氟甲基化的反式二取代烯烃2。然后，该序列涉及Sharpless不对称二羟基化，环状硫酸盐与NaN（3）的亲核打开，钯催化的选择性氢化和氧化。
• [EN] CANNABINOID RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS DE CANNABINOÏDES
  申请人：ARENA PHARM INC

  公开号：WO2011025541A1

  公开（公告）日：2011-03-03

  The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pain, for example bone and joint pain, muscle pain, dental pain, migraine and other headache pain, inflammatory pain, neuropathic pain, pain that occurs as an adverse effect of therapeutics and pain associated with osteoarthritis; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; CNS inflammation; atherosclerosis; undesired immune cell activity and inflammation; age-related macular degeneration; cough; leukemia; lymphoma; CNS tumors; prostate cancer; Alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis, and Parkinson's disease.

  本发明涉及某些化合物Ia的配方和调节大麻素CB2受体活性的药物组合物。本发明还涉及某些化合物Ia的配方和药物组合物，其调节CB1受体和CB2受体的活性。本发明的化合物和药物组合物用于治疗以下疾病的方法：疼痛，例如骨骼和关节疼痛，肌肉疼痛，牙痛，偏头痛和其他头痛，炎症性疼痛，神经痛，作为治疗的不良反应而发生的疼痛以及与骨关节炎相关的疼痛；痛觉过敏；触觉过敏；炎症性痛觉过敏；神经痛觉过敏；急性疼痛感；骨质疏松症；多发性硬化症相关的痉挛；自身免疫性疾病；过敏反应；中枢神经系统炎症；动脉粥样硬化；不良的免疫细胞活性和炎症；年龄相关的黄斑变性；咳嗽；白血病；淋巴瘤；中枢神经系统肿瘤；前列腺癌；阿尔茨海默病；中风引起的损伤；痴呆症；肌萎缩侧索硬化和帕金森病。
• CANNABINOID RECEPTOR MODULATORS
  申请人：Jones Robert M.

  公开号：US20120214766A1

  公开（公告）日：2012-08-23

  The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pain, for example bone and joint pain, muscle pain, dental pain, migraine and other headache pain, inflammatory pain, neuropathic pain, pain that occurs as an adverse effect of therapeutics and pain associated with osteoarthritis; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; CNS inflammation; atherosclerosis; undesired immune cell activity and inflammation; age-related macular degeneration; cough; leukemia; lymphoma; CNS tumors; prostate cancer; Alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis, and Parkinson's disease.

  本发明涉及公式Ia的某些化合物及其制药组合物，其调节大麻素CB2受体的活性。本发明还涉及公式Ia的某些化合物及其制药组合物，其调节CB1受体和CB2受体的活性。本发明的化合物和制药组合物适用于治疗以下疾病的方法：疼痛，例如骨骼和关节疼痛，肌肉疼痛，牙痛，偏头痛和其他头痛，炎性疼痛，神经痛，由治疗副作用引起的疼痛和与骨关节炎相关的疼痛；过敏症；炎性过敏症；神经病性过敏症；急性疼痛感受；骨质疏松症；多发性硬化症相关痉挛；自身免疫疾病；过敏反应；中枢神经系统炎症；动脉粥样硬化；不良的免疫细胞活动和炎症；年龄相关的黄斑变性；咳嗽；白血病；淋巴瘤；中枢神经系统肿瘤；前列腺癌；阿尔茨海默病；中风引起的损伤；痴呆症；肌萎缩性侧索硬化症和帕金森病。
• Cannabinoid receptor modulators
  申请人：Jones Robert M.

  公开号：US08778950B2

  公开（公告）日：2014-07-15

  The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pain, for example bone and joint pain, muscle pain, dental pain, migraine and other headache pain, inflammatory pain, neuropathic pain, pain that occurs as an adverse effect of therapeutics and pain associated with osteoarthritis; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; CNS inflammation; atherosclerosis; undesired immune cell activity and inflammation; age-related macular degeneration; cough; leukemia; lymphoma; CNS tumors; prostate cancer; Alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis, and Parkinson's disease.

  本发明涉及化合物Ia的某些化合物及其制药组合物，该化合物调节大麻素CB2受体的活性。本发明还涉及化合物Ia的某些化合物及其制药组合物，该化合物调节CB1受体和CB2受体的活性。本发明的化合物及其制药组合物适用于治疗以下疾病的方法：疼痛，例如骨骼和关节疼痛，肌肉疼痛，牙痛，偏头痛和其他头痛，炎症性疼痛，神经痛，作为治疗副作用发生的疼痛和与骨关节炎有关的疼痛；高痛觉性；触痛；炎症性高痛觉性；神经病性高痛觉性；急性伤害感受；骨质疏松症；多发性硬化相关痉挛；自身免疫性疾病；过敏反应；中枢神经系统炎症；动脉硬化；不良的免疫细胞活性和炎症；年龄相关的黄斑变性；咳嗽；白血病；淋巴瘤；中枢神经系统肿瘤；前列腺癌；阿尔茨海默病；中风引起的损伤；痴呆症；肌萎缩性侧索硬化症和帕金森病。
• ARYL LACTA KINASE INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20160333006A1

  公开（公告）日：2016-11-17

  The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.